STAT+: Cancer drug shortages keep disrupting patient care

STAT PlusNewsletterThe Readout Cancer drug shortages keep disrupting patient care Platinum chemotherapy’s long-term effects, surprising heart failure drug failures, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanSept. 11, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today?

Sign up to get our biotech newsletter in your inbox. Today: Cancer centers are grappling with persistent drug shortages, drug reps remain surprisingly entrenched in medical practice, and researchers find that platinum chemotherapy can leave lasting genetic scars in children.Advertisement It’s the 25th anniversary of 9/11. Surreal and solemn feelings come to mind.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended The Readout LOUD September 11, 2026 STAT Plus: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field The Readout September 10, 2026 STAT Plus: FDA expands Bayer lung cancer drug approval Advertisement Adam's Biotech Scorecard September 10, 2026 STAT Plus: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon Adam's Biotech Scorecard September 10, 2026 STAT Plus: What to expect from UniQure’s upcoming Huntington’s gene therapy readout The Readout September 9, 2026 STAT Plus: Orexin discoverers awarded prestigious Lasker award Subscriber Picks